MedTrace Logo

Cognitive and Cerebral Blood Flow Effects of 2-week Caffeine Abstinence or Maintenance

NCT01376882 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2013-03-29

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of 2 weeks caffeine abstinence as compared to 2 weeks caffeine maintenance (300mg per day)on cognition and mood. Cerebral blood flow effects will also be assessed in a subset of participants. The role of caffeine abstinence/maintenance in the acute effects of caffeine will also be explored.

Conditions

  • Cognitive Function
  • Mood
  • Cerebral Haemodynamics
  • Caffeine Withdrawal

Interventions

DIETARY_SUPPLEMENT

Placebo

Inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH. 1 Size 0 capsule 3 times a day for 14 days and 1 size 0 capsule on day 15.

DIETARY_SUPPLEMENT

Caffeine and Placebo

100 mg Caffeine capsules 3 times per day for 14 days and 1 size 0 capsule of inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH on day 15.

DIETARY_SUPPLEMENT

Placebo and Caffeine

Inert placebo capsules containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH, 1 Size 0 capsule 3 times a day for 14 days and a 100mg caffeine capsule on day 15.

DIETARY_SUPPLEMENT

Caffeine

Capsule containing 100 mg caffeine, one 3 times a day for 14 days and then one capsule on day 15.

Sponsors & Collaborators

  • Northumbria University

    lead OTHER

Principal Investigators

  • Crystal Haskell, PhD · Northumbria University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01376882 on ClinicalTrials.gov